High-resolution three‑dimensional contrast‑enhanced magnetic resonance venography in children: comparison of gadofosveset trisodium with ferumoxytol

Background Gadofosveset is a gadolinium-based blood pool contrast agent that was approved by the United States Food and Drug Administration in 2008. Its unanticipated withdrawal from production in 2016 created a void in the blood pool agent inventory and highlighted the need for an alternative agent...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric radiology 2022-03, Vol.52 (3), p.501-512
Main Authors: Shahrouki, Puja, Khan, Sarah N., Yoshida, Takegawa, Iskander, Paul J., Ghahremani, Shahnaz, Finn, J. Paul
Format: Article
Language:English
Subjects:
Aorta
Blood vessels
Child
Child, Preschool
Children
Contrast agents
Contrast Media
Ferrosoferric Oxide
Gadolinium
High resolution
Humans
Image acquisition
Image contrast
Image processing
Image quality
Imaging
Magnetic resonance
Magnetic Resonance Angiography - methods
Magnetic Resonance Spectroscopy
Medical imaging
Medical materials
Medical records
Medicine
Medicine & Public Health
Neuroradiology
Nuclear Medicine
Oncology
Organometallic Compounds
Original
Original Article
Patients
Pediatrics
Phlebography - methods
Qualitative analysis
Radiology
Retrospective Studies
Side effects
Signal to noise ratio
Ultrasound
Windows (intervals)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Gadofosveset is a gadolinium-based blood pool contrast agent that was approved by the United States Food and Drug Administration in 2008. Its unanticipated withdrawal from production in 2016 created a void in the blood pool agent inventory and highlighted the need for an alternative agent with comparable imaging properties. Objective The purpose of our study is to compare the diagnostic image quality, vascular contrast-to-noise ratio (CNR) and temporal signal characteristics of gadofosveset trisodium and ferumoxytol at similar molar doses for high-resolution, three-dimensional (3-D) magnetic resonance (MR) venography in children. Materials and methods The medical records and imaging data sets of patients who underwent high-resolution 3-D gadofosveset-enhanced MR venography (GE-MRV) or ferumoxytol-enhanced MR venography (FE-MRV) were retrospectively reviewed. Two groups of 20 pediatric patients (age- and weight-matched with one patient common to both groups; age range: 2 days–15 years) who underwent high-resolution 3-D GE-MRV or FE-MRV at similar molar doses were identified and analyzed. Qualitative analysis of image quality and vessel definition was performed by two blinded pediatric radiologists. Interobserver agreement was assessed with the AC1 (first-order agreement coefficient) statistic. Signal-to-noise ratio (SNR) and CNR of the inferior vena cava and aorta were measured in the steady-state venous phase. Medical records were retrospectively reviewed for any adverse reactions associated with either contrast agent. Results Measured SNR and CNR of the inferior vena cava were higher for FE-MRV than GE-MRV ( P  = 0.034 and P  
ISSN:0301-0449
1432-1998
DOI:10.1007/s00247-021-05225-2